πŸ‡ΊπŸ‡Έ FDA
Patent

US 10815301

Anti-CD30 chimeric antigen receptors

granted A61KA61K2039/505A61P

Quick answer

US patent 10815301 (Anti-CD30 chimeric antigen receptors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61P, A61P35/00